<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01589666</url>
  </required_header>
  <id_info>
    <org_study_id>RSX-102</org_study_id>
    <nct_id>NCT01589666</nct_id>
  </id_info>
  <brief_title>Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers</brief_title>
  <official_title>Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entegrion, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Entegrion, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, single-center, open-label, ascending dose study which will assess
      the safety and tolerability of 5 doses of spray-dried solvent/detergent treated plasma
      (Resusix®) in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">September 9, 2016</completion_date>
  <primary_completion_date type="Actual">September 9, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent SAEs</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of treatment-emergent SAEs reported for up to 12 weeks post Resusix infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of select coagulation factors</measure>
    <time_frame>30 minutes post infusion</time_frame>
    <description>To evaluate the recovery of select coagulation factors after infusion of 2 Resusix</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the incidence of AEs for up to 12 weeks after infusion of Resusix</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Coagulation Defects</condition>
  <arm_group>
    <arm_group_label>Spray-dried S/D-treated plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resusix (Spray-Dried Solvent/Detergent-Treated Plasma) uses source plasma from U.S.-licensed facilities as the starting material. Source plasma donors are selected from the AB blood type, which is considered a &quot;universal&quot; product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Spray-dried S/D-treated Plasma</intervention_name>
    <description>Infusion of 100 mL Spray-dried S/D-treated Plasma</description>
    <arm_group_label>Spray-dried S/D-treated plasma</arm_group_label>
    <other_name>Resusix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spray-dried S/D-treated plasma</intervention_name>
    <description>Infusion of 200mL Spray-dried S/D-treated plasma</description>
    <arm_group_label>Spray-dried S/D-treated plasma</arm_group_label>
    <other_name>Resusix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Spray-dried S/D-treated Plasma</intervention_name>
    <description>Infusion of 500 mL Spray-dried S/D-treated plasma</description>
    <arm_group_label>Spray-dried S/D-treated plasma</arm_group_label>
    <other_name>Resusix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Spray-dried S/D-treated Plasma</intervention_name>
    <description>Infusion of 750 mL Spray-dried S/D-treated Plasma</description>
    <arm_group_label>Spray-dried S/D-treated plasma</arm_group_label>
    <other_name>Resusix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Spray-dried S/D-treated Plasma</intervention_name>
    <description>Infusion of 800 mL Spray-dried S/D-treated Plasma</description>
    <arm_group_label>Spray-dried S/D-treated plasma</arm_group_label>
    <other_name>Resusix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must provide written informed consent for participation in this study and
             valid contact information.

          2. Subject must be a male or postmenopausal female.

          3. Subject must be at least 18 years of age and not older than 55 years of age.

          4. Subject must be in good general health, with no significant medical history, have no
             clinically significant abnormalities on physical examination at Screening, including
             no history or symptoms of respiratory or cardiac disease.

          5. Vital signs should be within normal limits at Screening:

               1. Body temperature within 97°F to 99°F

               2. Heart rate 45 to 100 beats per minute (bpm)

               3. Systolic blood pressure (SBP) within 90 to 140 mmHg and DBP within 50 to 90 mmHg.

          6. Subject must have a normal (no clinically significant abnormality) EKG at Screening
             and prior to administration of Resusix

               1. PR interval within 120 and 200 mm/s

               2. QRS interval &lt;120 mm/s

               3. QTc interval ≤440 mm/s

          7. Subject must have laboratory hematology values within following normal ranges:

               1. White blood cell count (WBC): 4,500 to 11,000/mL

               2. Platelet (PLT) count: 150,000 to 400,000/mL;

               3. Hemoglobin (Hb): 12.5 to 15.5 g/dL;

               4. Activated partial thromboplastin time (aPTT): 24.6 to 36.7 seconds;

               5. Normal PT, International Normalized Ratio (INR): 0.8 to 1.2;

               6. Protein C ≥90%, Protein S ≥77%;

               7. Antithrombin III levels (ATIII) ≥100%.

          8. Subject must have laboratory clinical chemistry values within normal range specified
             by the testing laboratory.

          9. BMI ≤30 kg/m2.

         10. Subject must have a negative toxicology screening panel (urine test including
             qualitative identification of PCP, barbiturates, THC, amphetamines, benzodiazepines,
             opiates, and cocaine.)

         11. Subject must be a non-drinker (≤2 alcoholic beverages per week) and a non-smoker (any
             tobacco products within six months prior to Screening).

         12. Subject must have no history of recreational (including IV) drug use (by
             self-declaration).

         13. Subject must have the ability and willingness to attend frequent visits to the study
             center.

        Exclusion Criteria:

          1. Subject with lower extremity deep vein thrombosis (DVT) at Screening.

          2. Subject has a history of coagulopathy or thromboembolic disease.

          3. Subject has a first degree family member with history of venous thromboembolic disease
             &lt;55 years of age or arterial thromboembolic disease &lt;45 years of age.

          4. Subject has documented drug allergies with well-described reactions.

          5. Subject has hepatomegaly, splenomegaly, adenopathy, bruising, and/or ecchymoses
             identified at Screening.

          6. Subject is found to have positive NAT test for HIV, HBV or HCV.

          7. Subject has any murmurs, rubs, or gallops on cardiac auscultation.

          8. Subject has had a previous transfusion at any time.

          9. Subject is unlikely to comply with the study protocol or, in the opinion of the
             investigator, would not be a suitable candidate for participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Vince, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vince &amp; Associates Clinical Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>April 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Entegrion</keyword>
  <keyword>Spray-dried Solvent/Detergent Plasma</keyword>
  <keyword>Fresh Frozen Plasma</keyword>
  <keyword>Transfusion</keyword>
  <keyword>Resuscitation</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Coagulopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

